


Greetings from Dr. Qureshi

Dear ATACH-II Colleagues:

National Taiwan University Hospital's enrollment on November 25th marked the 400th subject enrolled in the ATACH-II trial. Thank you to all clinical sites that contributed to the accomplishment of this important milestone. We are now close to reaching the one third mark of our enrollment goal of 1,280 subjects. Last quarter's enrollments - October 32 - November 35 - December 26 - demonstrate that we are close to reaching the necessary monthly enrollment target of 40 subjects.

As the ATACH-II trial enters its fourth year, we are excited about our partnership with the Neurological Emergencies Treatment Trials ("NETT") Clinical Coordinating Center ("CCC"). Beginning in January 2014, the staff at the NETT CCC will assist with the management of all US clinical sites. We look forward to this collaboration and the additional clinical sites within the NETT network.

Many thanks for all your efforts towards the ATACH-II trial.




Dr. Qureshi catches up with Congressman Keith Ellison representing Minnesota's 5th District.

Inside This Issue...

- ATACH-II Lessons Learned
- New Team Member Bio
- ATACH-II Leaderboard
- Country Leaderboard
- ATACH-II Clinical Trial - An Illustration
- Recent DSMB Meetings
- Recent Investigator Meetings
- Dear Logan – Q & A
- ATACH-II Investigators Meeting at the ISC 2014 in San Diego
- Contact Information

Clinical Coordinating Center

Zeenat Qureshi Stroke Research Center
Department of Neurology, University of Minnesota
420 Delaware Street S.E. • Minneapolis, Minnesota 55455
Phone: (612) 625-6974 | Fax: (612) 625-7950
www.atach2.com



UNIVERSITY OF MINNESOTA

ATACH-II Lessons Learned - A Look Back

1. Ensure that intensive SBP reduction meets the SBP goals (<140 mm Hg) effectively and consistently. A mere difference from standard SBP reduction may not adequately test the primary hypothesis.
2. Monitor time to initiate treatment and post 24 hr BP management to avoid differences secondary to unblinded nature of trial.
3. No modification in inclusion/exclusion criteria as there was no heterogeneity of the treatment effect on the primary outcome prespecified in INTERACT II.
4. Safety profile may be different with greater magnitude of SBP reduction.
5. Maintain a low proportion of untreated patients to adequately test pharmacological reduction as an intervention.

Getting to Know the ATACH-II Team - Welcome Christina Carroll

Christina Carroll - ATACH-II Project Monitor



Where did you grow up?

Grew up in Lansing, Michigan and spent some years in NYC.

Who is your favorite writer?

Sandra Cisneros.

What is the best advice you've ever received? Do what makes you happy!

If you could travel anywhere,

where would you like to go? Turks and Caicos.

How did you become interested in clinical research?

Losing a family member and also my overall empathy and compassion for people. I wanted to contribute to research as well as be a part of the healing process.

What's one of your favorite habits you have? Going to the coffee shop-Love PEETS coffee :)

Do you like to plan things out in detail or be spontaneous? I'd say a little bit of both...At times I plan, but I am also very spontaneous!

What's the best decision you ever made? Moving back to Michigan in 2009, although I do miss the Austin weather.

Key Enrollment
Information for
ATACH-II

www.atach2.com

24-Hour Hotline: (612) 347-5710

Tell dispatch: I have a question regarding the ATACH-II Clinical Trial

To randomize: <http://dcu.musc.edu/ctms/>


ATACH-II Leaderboard

Rank	Site Name	Country	#	Principal Investigator(s)	Primary Study Coordinator
1	National Cerebral and Cardiovascular Center	Japan	42	Kazunori Toyoda	Kanae Hirase
2	Beijing Tiantan Hospital	China	35	Wang Yongjun	Zeyu Ding
3	Kobe City Medical Center General Hospital	Japan	18	Nobuyuki Sakai	Miyuki Okitsu
4	Abington Memorial Hospital	USA	18	Qaisar Shah	Karin Jonczak
5	New Jersey Neuroscience Institute, JFK Medical Center	USA	17	Jawad Kirmani	Charles Porbeni
6	Columbia University	USA	15	Stephan Mayer	Christina Faló
7	Baylor College of Medicine	USA	14	Jose Suarez	Eusebia Calvillo
8	The First People's Hospital of Taizhou	China	13	Zhimin Wang	Jiangxian Ying
9	St. Cloud Hospital	USA	12	M. Fareed Suri	Melissa Freese
10	Guilford Neurologic Associates	USA	12	Pramod Sethi	Wesley Harbison
	Trial Total		436		

International Leaderboard

Rank	Country	Enrollments	Sites
1	United States	216	48
2	Japan	115	15
3	China	62	4
4	Taiwan	34	7
5	South Korea	9	4

ATACH-II Clinical Trial - An Illustration



Recent DSMB Meetings

November 1, 2013

The DSMB recommended to NINDS that clevidipine not be allowed as an alternative to nicardipine for the ATACH-II trial.

October 6, 2013

DSMB had no safety concerns and recommended the study continue.

April 22, 2013

DSMB reviewed the safety and overall progress of the trial: found everything to be satisfactory and recommended the study proceed as planned.

Next DSMB meeting is scheduled for **May 6, 2014**.

Recent ATACH-II Investigator Meetings



Regional Investigators Meeting
held in Philadelphia on October 10, 2013



International Investigators Meeting
held in Osaka, Japan on October 6, 2013



The Data and Clinical Coordinating Centers from the Medical School of South Carolina, the University of Minnesota and the University of Michigan met on December 5, 2013 in Ann Arbor, Michigan to discuss ATACH-II.

Dear Logan - Q & A about Imaging Procedure

As the Assistant to the Image Analyst, I often receive questions pertaining to how the images should arrive at the CCC. In this column I will answer a couple of those questions.

Dear Logan,

Let me start by saying that I really enjoy your column - it is the best. As for my question, the protocol states that the images need to be de-identified, what information needs to be removed? Also, how should I label the discs?

- Earl Lee Riser

Good morning,

Thank you for the high praise. I am grateful to have such loyal fan base prior to writing a single column. The following information should be removed from each image: (1) the subject's name, (2) date of birth, (3) name of referring physician, and (4) assigned WebDCU subject number.

As for labeling, it is easiest to label the front of the disc. The label should include (1) the subject ID number, (2) the CT tracking number - or modality and date and time.

Example Label 1
Subject ID #5555
CT 1111

Example Label 2
Subject ID #55555
CTA 10/10/10 14:53

- Logan

Dear Logan,

I am not sure where I should send the images? #wheredotheimagesgo?

- Penny Lane

Dear Penny,

The images should be sent to the following address:

Logan Brau
UMMC-Neurology
516 Delaware ST SE, 12-100
MMC 295
Minneapolis, Minnesota 55455

- Save a penny and use our FedEx account. Logan

Dr. Adnan Qureshi visits
the University of Florida
Gainesville for Grand Rounds.



ATACH-II

2014 Investigators' Meeting

San Diego, CA

Save the Date

Thursday, February 13

7 - 8:30 PM

during

ISC 2014

(venue to be announced with invitation)

5:30 - 7:00 PM:

Presentations for additional ICH Trials
MISTIE-III, CLEAR-III, ICES-II held in conjunction





Dr. Qureshi visits the study team at Wayne State on December 6, 2013.

The latest contact information for ATACH-II.

Don't hesitate to reach out to us - we are here to help you! Need help with an enrollment or other ATACH-II emergency? Call 612-347-5710 and you will be routed through a list of qualified individuals to ensure you're connected with a core team member who is available to help you immediately.

General Questions? Contact Kathy France at 612-625-6974 or kafrance@umn.edu

Contract or Reimbursement Questions? Contact Emily Abbott at 612-625-0551 or eiabbott@umn.edu

WebDCU questions? Contact Catherine Dillon at 843-876-1942 or rileycp@musc.edu

To avoid delay in receipt of study drug, please email requests for additional drug to atachstudydrug@gmail.com



Clinical Coordinating Center

Zeenat Qureshi Stroke Research Center
University of Minnesota, Department of Neurology
MMC 295, 420 Delaware St. S.E.
Minneapolis, MN 55455

Phone: (612) 625-6974 Fax: (612) 625-7950



Statistical and Data Coordination Center

Medical University of South Carolina -
Division of Biostatistics & Epidemiology
135 Cannon Street, Ste 303 MSC 835
Charleston, SC 29425

Phone: (843) 876-1919 Fax: (843) 876-1923

Funded by NIH through grants U01NS062091 and R01NS061861; The content is solely the responsibility of the authors and does not necessarily represent the official views of NINDS or NIH.